Holen Sie sich die Stockscreener-App
38.67
2.67%
-1.06
Handel nachbörslich:
39.44
0.77
+1.99%
Schlusskurs vom Vortag:
$39.73
Offen:
$39.78
24-Stunden-Volumen:
4.34M
Relative Volume:
1.01
Marktkapitalisierung:
$16.52B
Einnahmen:
$2.31B
Nettoeinkommen (Verlust:
$1.66B
KGV:
16.84
EPS:
2.297
Netto-Cashflow:
$827.02M
1W Leistung:
-3.08%
1M Leistung:
+0.29%
6M Leistung:
+14.48%
1J Leistung:
+49.25%
1-Tages-Spanne:
$38.60
$39.78
1-Wochen-Bereich:
$38.60
$40.21
52-Wochen-Spanne:
$24.05
$41.24
Royalty Pharma Plc Stock (RPRX) Company Profile
Firmenname
Royalty Pharma Plc
Sektor
Branche
Telefon
(212) 883-0200
Adresse
110 EAST 59TH STREET, NEW YORK, NY
Vergleichen Sie RPRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
38.67 | 16.97B | 2.31B | 1.66B | 827.02M | 2.297 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.04 | 115.56B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
703.26 | 75.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
430.02 | 60.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
900.76 | 55.48B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
196.55 | 43.51B | 447.02M | -1.18B | -906.14M | -6.1812 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-30 | Eingeleitet | Goldman | Buy |
| 2025-05-16 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-06-03 | Herabstufung | UBS | Buy → Neutral |
| 2022-06-14 | Fortgesetzt | UBS | Buy |
| 2022-05-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-04-27 | Eingeleitet | Goldman | Buy |
| 2022-04-14 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-10-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-07-30 | Eingeleitet | Tigress Financial | Buy |
| 2020-11-09 | Hochstufung | UBS | Neutral → Buy |
| 2020-07-14 | Eingeleitet | Evercore ISI | In-line |
| 2020-07-13 | Eingeleitet | BofA Securities | Buy |
| 2020-07-13 | Eingeleitet | Citigroup | Neutral |
| 2020-07-13 | Eingeleitet | Cowen | Outperform |
| 2020-07-13 | Eingeleitet | Goldman | Neutral |
| 2020-07-13 | Eingeleitet | JP Morgan | Neutral |
| 2020-07-13 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-07-13 | Eingeleitet | SunTrust | Buy |
| 2020-07-13 | Eingeleitet | UBS | Neutral |
Alle ansehen
Royalty Pharma Plc Aktie (RPRX) Neueste Nachrichten
Denali enters into a $275M funding deal with Royalty Pharma - MSN
Royalty Pharma (NASDAQ:RPRX) EVP Sells $4,374,700.00 in Stock - MarketBeat
11% Of This Royalty Pharma Insider's Holdings Were Sold - 富途牛牛
Royalty Pharma Insider Sold Shares Worth $4,375,008, According to a Recent SEC Filing - marketscreener.com
What's Going On With Denali Therapeutics Stock Friday?Denali Therapeutics (NASDAQ:DNLI) - Benzinga
Denali Enters Into a $275M Funding Deal With Royalty Pharma - Yahoo Finance
Royalty Pharma PLC $RPRX Shares Acquired by Schroder Investment Management Group - MarketBeat
Will Royalty Pharma plc (RPD) stock maintain strong growth2025 Valuation Update & Reliable Volume Spike Trade Alerts - Newser
Royalty Pharma (NASDAQ:RPRX) CFO Sells $2,774,234.34 in Stock - MarketBeat
Insider Selling: Royalty Pharma (NASDAQ:RPRX) EVP Sells $931,686.69 in Stock - MarketBeat
Is Royalty Pharma plc stock a good choice for value investors2025 Market Sentiment & Verified Technical Trade Signals - Newser
Denali Therapeutics stock rises on $275 million royalty deal with Royalty Pharma - Investing.com Australia
Denali, Royalty Pharma Ink $275Mln Royalty Financing Agreement - Nasdaq
Denali Therapeutics and Royalty Pharma ink $275 million funding deal By Investing.com - Investing.com Nigeria
Royalty Pharma, Denali Sign $275 Million Hunter Syndrome Treatment Royalty Deal - marketscreener.com
Denali Therapeutics enters $275 million royalty funding agreement with Royalty Pharma - Investing.com
How Royalty Pharma plc (RPD) stock correlates with oil marketsMarket Activity Summary & Capital Efficiency Focused Strategies - Newser
Denali Therapeutics and Royalty Pharma ink $275 million funding deal - Investing.com India
Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Agreement for Tividenofusp Alfa Development - Quiver Quantitative
Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement - The Manila Times
OMERS ADMINISTRATION Corp Decreases Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Is Royalty Pharma plc (RPD) stock attractive post correction2025 Trading Volume Trends & Real-Time Market Sentiment Alerts - Newser
How Royalty Pharma plc (RPD) stock trades pre earningsQuarterly Profit Summary & Weekly High Return Forecasts - Newser
How Royalty Pharma plc (RPD) stock performs in easing cyclesJuly 2025 Action & Community Consensus Stock Picks - Newser
Arrowstreet Capital Limited Partnership Purchases 1,615,706 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma EVP Coyne sells shares worth $2.77 million By Investing.com - Investing.com Nigeria
Urist Marshall sells Royalty Pharma (RPRX) shares worth $1.66 million By Investing.com - Investing.com Nigeria
Transcript : Royalty Pharma plc Presents at Evercore 8th Annual Healthcare Conference, Dec-03-2025 03 - marketscreener.com
Urist Marshall sells Royalty Pharma (RPRX) shares worth $1.66 million - Investing.com
100,000 Shares in Royalty Pharma PLC $RPRX Acquired by Watchtower Advisors LP - MarketBeat
Norges Bank Invests $181.39 Million in Royalty Pharma PLC $RPRX - MarketBeat
Korea Investment CORP Sells 160,900 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC $RPRX Shares Purchased by River Road Asset Management LLC - MarketBeat
Why Royalty Pharma plc (RPD) stock could break out in 2025July 2025 Spike Watch & Precise Swing Trade Entry Alerts - Newser
Technical Reactions to RPRX Trends in Macro Strategies - news.stocktradersdaily.com
Royalty Pharma PLC $RPRX Shares Sold by Charles Schwab Investment Management Inc. - MarketBeat
Royalty Pharma PLC $RPRX Shares Sold by Elo Mutual Pension Insurance Co - MarketBeat
Patient Capital Management LLC Buys 15,342 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Northwest & Ethical Investments L.P. Takes $1.67 Million Position in Royalty Pharma PLC $RPRX - MarketBeat
Russell Investments Group Ltd. Sells 286,493 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma (NASDAQ:RPRX) Stock Rating Lowered by Wall Street Zen - MarketBeat
Franklin Resources Inc. Buys 151,248 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma Insider Sold Shares Worth $2,682,505, According to a Recent SEC Filing - marketscreener.com
Creative Planning Buys 9,718 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma’s Q3 2025 Earnings Call Highlights - MSN
Terrance Coyne Sells 69,582 Shares of Royalty Pharma (NASDAQ:RPRX) Stock - MarketBeat
Is Royalty Pharma PLC Gaining or Losing Market Support? - Benzinga
Rhenman & Partners Asset Management AB Lowers Stock Position in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma EVP Coyne sells $2.68 million in shares By Investing.com - Investing.com South Africa
Royalty Pharma EVP Coyne sells $2.68 million in shares - Investing.com
RPRX CFO Terrance P. Coyne reports 10b5-1 share sales - Stock Titan
Finanzdaten der Royalty Pharma Plc-Aktie (RPRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Royalty Pharma Plc-Aktie (RPRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Coyne Terrance P. | EVP & CFO |
Dec 01 '25 |
Sale |
39.87 |
69,582 |
2,773,956 |
47,260 |
| Urist Marshall | EVP, Research & Investments |
Dec 01 '25 |
Sale |
39.93 |
23,333 |
931,633 |
183,334 |
| Urist Marshall | EVP, Research & Investments |
Dec 01 '25 |
Sale |
39.90 |
18,242 |
727,856 |
25,640 |
5.68%
0.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):